ASO treatment resulted in greater than fourfold improvement in survival of the DS mice. The expression of NaV1.1 protein increased in ASO‐treated DS mouse brains to amounts indistinguishable from WT brains. Increase survival, decrease fewer seizures and latency to the first seizure was prolonged. Here, SCN1A is linked to Dravet syndrome.